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Guilherme Macedo -conception and design of the study; acquisition of data; analysis and interpretation of data; critical revision of the article; final approval of the submitted version. In fact, most of the available data evaluating the impact of HCV eradication on HCC risk is from peginterferon based treatments, and patients with a previous treated HCC were seldomly included due to the profile of side effects. These studies have shown that cirrhotic patients achieving a sustained virological response (SVR), with regimens containing interferon, were associated with a lower risk of HCC development and annual incidence rates of 1.2-1.4% (2,3).
Nonetheless, there are some concerns regarding selection bias, as patients with more advanced disease and older age were less likely to be included in clinical trials and have access to treatment, and the main risk factors identified for HCC after HCV eradication are similar to the risk factors for worse SVR with peginterferon.
In this study by María Reig et al. the included patients performed at least one dynamic radiological tumor assessment after starting antiviral therapy. This methodological design was very important to prevent diagnostic bias, as in most large-scale retrospective studies it is difficult to ascertain the standard surveillance and the respective patient adherence.
With the same concern, we wish to report an increased rate of HCC incidence in patients with hepatitis C associated cirrhosis that underwent successful interferon-free antiviral therapy, at our institution.
From a group of 240 patients that were treated with inferferon-free regimens for hepatitis C, we evaluated all patients with liver cirrhosis that performed regular HCC screening after the start of antiviral therapy. Those with "non-characterized nodules" and a previous diagnosis of HCC were excluded. We included 54 patients that were treated with sofosbuvir and ledipasvir for 24 weeks in 2015.
After a median follow-up of 12.0 months (IQR 9.4 -12.5 months), since viral suppression, 7.4% were diagnosed with HCC. The median time for HCC development was 7.6 months (IQR 6.3 -10.6 months), after HCV RNA undetectability. The overall characterization of the included patients is presented in Table 1 . The de-novo HCC patients were detected without specific symptoms in ultrasonographic surveillance program and had diagnostic criteria at dynamic CT or MRI, that were validated in the multidisciplinary oncological meeting, according to EASL guidelines (4). All patients were referred for HCC treatment with liver transplantation and /or locoregional therapy.
The detected HCC incidence (7.4% in the first year), in cirrhotic patients achieving SVR, was higher than the previously reported for regimens containing interferon (1.2-1.4%). The affected patients had no significant differences in baseline variables that could be associated with an increased HCC risk, namely regarding age, HCV genotype, HVC viral load, IL28B single-nucleotide polymorphism, APRI score and liver function assessed by Child-Pugh or Meld score (5, 6) . Furthermore, there seems to be no selection bias regarding eligibility to peginterferon treatment, as most affected patients did not have contraindications for this less effective therapy.
We agree with María Reig et al. that a direct oncogenic effect of the antivirals is highly unlikely, but due to the coincidence with viral clearance the responsible mechanisms will probably be similar. In fact, the increased incidence comparing to peginterferon treatment suggests an important role of the immune system. In their study they performed a thorough discussion about the mechanisms that Another concern is that clinical trials and other cohorts have not yet reported the same findings regarding HCC incidence, which could be related with study design, follow-up time and HCC screening implementation. Nevertheless, these results should be evaluated in larger studies, specifically addressing patients with significant fibrosis.
